140 related articles for article (PubMed ID: 30740257)
1. Development of a competitive enzyme-linked immunosorbent assay for therapeutic drug monitoring of afatinib.
Sogawa R; Saita T; Yamamoto Y; Kimura S; Narisawa Y; Kimura S; Shin M
J Pharm Anal; 2019 Feb; 9(1):49-54. PubMed ID: 30740257
[TBL] [Abstract][Full Text] [Related]
2. Quantitative determination of erlotinib in human serum using competitive enzyme-linked immunosorbent assay.
Yamamoto Y; Saita T; Yamamoto Y; Shin M
J Pharm Anal; 2018 Apr; 8(2):119-123. PubMed ID: 29736298
[TBL] [Abstract][Full Text] [Related]
3. Quantification of Sorafenib in Human Serum by Competitive Enzyme-Linked Immunosorbent Assay.
Saita T; Yamamoto Y; Noda S; Shioya M; Hira D; Andoh A; Morita SY; Terada T; Shin M
Biol Pharm Bull; 2015; 38(11):1788-93. PubMed ID: 26521829
[TBL] [Abstract][Full Text] [Related]
4. Development of a Competitive Enzyme-Linked Immunosorbent Assay for the Determination of Sunitinib Unaffected by Light-Induced Isomerization.
Kataoka H; Saita T; Sogawa R; Yamamoto Y; Matsuo S; Kimura S; Kimura S; Shin M
Biol Pharm Bull; 2021; 44(10):1565-1570. PubMed ID: 34602567
[TBL] [Abstract][Full Text] [Related]
5. Development of a specific and sensitive enzyme-linked immunosorbent assay for the quantification of imatinib.
Saita T; Shin M; Fujito H
Biol Pharm Bull; 2013; 36(12):1964-8. PubMed ID: 24292055
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of an ELISA with high sensitivity for therapeutic monitoring of afatinib.
Al-Shehri MM; El-Gendy MA; El-Azab AS; Hamidaddin MA; Darwish IA
Bioanalysis; 2018 Sep; 10(18):1511-1523. PubMed ID: 30117333
[TBL] [Abstract][Full Text] [Related]
7. A specific and sensitive assay for gefitinib using the enzyme-linked immunosorbent assay in human serum.
Saita T; Fujito H; Mori M
Biol Pharm Bull; 2005 Oct; 28(10):1833-7. PubMed ID: 16204931
[TBL] [Abstract][Full Text] [Related]
8. An Indirect Competitive Enzyme-Linked Immunosorbent Assay for the Determination of Brigatinib and Gilteritinib Using a Specific Polyclonal Antibody.
Kataoka H; Saita T; Oka A; Yamada M; Shin M
Biol Pharm Bull; 2022; 45(7):904-909. PubMed ID: 35786598
[TBL] [Abstract][Full Text] [Related]
9. Development of enzyme-linked immunosorbent assay for therapeutic drug monitoring of mexiletine.
Saita T; Fujito H; Mori M
Biol Pharm Bull; 2003 Jun; 26(6):761-5. PubMed ID: 12808282
[TBL] [Abstract][Full Text] [Related]
10. Determination of tyrosine kinase inhibitor afatinib in rat plasma using LC-MS/MS and its application to in vivo pharmacokinetic studies of afatinib liposomes.
Lu X; Liu S; Yang X; Han M; Sun K
J Pharm Biomed Anal; 2019 Feb; 164():181-186. PubMed ID: 30390560
[TBL] [Abstract][Full Text] [Related]
11. Effects of pharmacokinetics-related genetic polymorphisms on the side effect profile of afatinib in patients with non-small cell lung cancer.
Hayashi H; Iihara H; Hirose C; Fukuda Y; Kitahora M; Kaito D; Yanase K; Endo J; Ohno Y; Suzuki A; Sugiyama T
Lung Cancer; 2019 Aug; 134():1-6. PubMed ID: 31319966
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous and rapid determination of gefitinib, erlotinib and afatinib plasma levels using liquid chromatography/tandem mass spectrometry in patients with non-small-cell lung cancer.
Hayashi H; Kita Y; Iihara H; Yanase K; Ohno Y; Hirose C; Yamada M; Todoroki K; Kitaichi K; Minatoguchi S; Itoh Y; Sugiyama T
Biomed Chromatogr; 2016 Jul; 30(7):1150-1154. PubMed ID: 26525154
[TBL] [Abstract][Full Text] [Related]
13. A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403.
Oda N; Hotta K; Ninomiya K; Minami D; Ichihara E; Murakami T; Yokoyama T; Ichikawa H; Chikamori K; Takigawa N; Ochi N; Harita S; Maeda Y; Kiura K
Cancer Chemother Pharmacol; 2018 Dec; 82(6):1031-1038. PubMed ID: 30276451
[TBL] [Abstract][Full Text] [Related]
14. An ultra-specific and sensitive sandwich ELISA for imatinib using two anti-imatinib antibodies.
Saita T; Yamamoto Y; Hosoya K; Yamamoto Y; Kimura S; Narisawa Y; Shin M
Anal Chim Acta; 2017 May; 969():72-78. PubMed ID: 28411632
[TBL] [Abstract][Full Text] [Related]
15. A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [(11)C]erlotinib and [(18)F]afatinib in lung cancer-bearing mice.
Slobbe P; Windhorst AD; Stigter-van Walsum M; Smit EF; Niessen HG; Solca F; Stehle G; van Dongen GA; Poot AJ
EJNMMI Res; 2015; 5():14. PubMed ID: 25853020
[TBL] [Abstract][Full Text] [Related]
16. The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer.
Yonesaka K; Kudo K; Nishida S; Takahama T; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Okamoto I; Nishio K; Nakagawa K
Oncotarget; 2015 Oct; 6(32):33602-11. PubMed ID: 26418897
[TBL] [Abstract][Full Text] [Related]
17. ELISA for the quantification of pilsicainide.
Saita T; Fujito H; Mori M
Biol Pharm Bull; 2001 Oct; 24(10):1113-6. PubMed ID: 11642313
[TBL] [Abstract][Full Text] [Related]
18. Enzyme-linked immunosorbent assay (ELISA) for luteinizing hormone releasing hormone (LH-RH) using a heterobifunctional cross-linking agent, N-[beta-(4-diazophenyl)ethyl]maleimide.
Fujiwara K; Saita T; Kitagawa T
Biol Pharm Bull; 1993 Nov; 16(11):1073-7. PubMed ID: 8312857
[TBL] [Abstract][Full Text] [Related]
19. Development of an enzyme-linked immunosorbent assay for the quantification of O-Phosphoethanolamine in human plasma.
Saita T; Kataoka H; Sogawa R; Hayama T; Tomita R; Monji A; Mizoguchi Y; Shimanoe C
Anal Biochem; 2022 Dec; 659():114952. PubMed ID: 36228715
[TBL] [Abstract][Full Text] [Related]
20. Development and evaluation of a direct sandwich-enzyme-linked immunosorbent assay for the quantification of human hepatic triglyceride lipase mass in human plasma.
Nishimura M; Ohkaru Y; Ishii H; Sunahara N; Takagi A; Ikeda Y
J Immunol Methods; 2000 Feb; 235(1-2):41-51. PubMed ID: 10675756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
